Abstract: Several embodiments of the invention relate generally to a system and methods for the treatment of gaseous emissions comprising methane and one or more non-methane compounds that can influence the metabolism of methane-oxidizing microorganisms. In several embodiments, there is provided a system and methods for the treatment of methane emissions through the use of methanotrophic microorganisms to generate functionally consistent and harvestable products. Certain embodiments of the invention are particularly advantageous because they reduce environmentally-destructive methane emissions and produce harvestable end-products.

Abstract: Disclosed are techniques and systems for producing microbials having anaplerotic oils that are rich in odd-chain fatty acids, and other beneficial components, at higher concentrations than those present in other natural dietary sources of OCFA, at lower cost, and higher production yield. Further, disclosed are examples of incorporation of these higher concentration OCFA products into food for human and non-human animal consumption.

Abstract: An active ingredient complex is effective to treat, reduce the likelihood of developing, reduce the severity of, or ameliorate acute alcoholic liver damage or the symptoms of a hangover. In some embodiments, the active ingredient complex includes NADH (nicotinamide adenine dinucleotide (NAD)+hydrogen (H)), L-cysteine, dihydromyricetin (DHM), N-acetyl-cysteine (NAC), L-theanine, and buffered vitamin C, or pharmaceutically acceptable salts or derivative thereof. According to some embodiments, a pharmaceutical composition or dietary supplement may include the active ingredient complex and one or more pharmaceutically acceptable carriers, excipients, adjuvants and/or diluents.

Abstract: The present invention relates generally to probiotics, in particular probiotics capable of bio-converting olive polyphenols. The invention relates to a method of selecting a probiotic strain or probiotic strain mixture. Further aspects of the invention include the use of a probiotic strain to increase the bio-efficacy of olive polyphenols and a composition comprising a probiotic strain for use in the potentiation of a therapeutic effect and/or a prophylactic effect of oleuropein.

Abstract: Tissue and organ transplantation success is chiefly dependent on the harvest and preservation techniques employed. Yield and quality enhancements are needed, because qualified patient demand far outpaces donors and ultimately, tissues and organs stored and transported so as to render them in acceptable condition for surgery. In the case of corneal transplants, tissue supplies help 1 out of 70 patients in need despite being among the most successful such procedures today. Transplant success has improved overall with enhanced storage and transport methods that have allowed for greater time and distances to reach patients in need, whether corneas, kidneys, hearts, lungs, livers or other tissues, limbs or cellular materials. While corneal tissues specifically benefit from oxygenation via direct air contact and normal tears in a healthy individual, once donated, the lack of corneal vascularization can uniquely accelerate the depletion of oxygen that occurs upon harvesting of all transplant materials.

Abstract: Described herein are methods and compositions for the use of treating damage induced by SD. Aspects of the invention relate to administering to a subject in need thereof an agent that reduces reactive oxygen species. In some embodiments, administration of an agent that reduces reactive oxygen species repairs SD-induced damage in the gut.

Abstract: The present invention relates to a method of transporting a stem cell population, the method comprising transporting the stem cell population contacted with a liquid carrier. In addition, the present invention concerns a method of treating a subject having a disease, the method comprising topically administering a defined mesenchymal stem cell population to the subject, wherein the mesenchymal stem cell population is administered within about 96 hours from the time point the mesenchymal stem cell population has been harvested. Also concerned is a unit dosage comprising about 20 million cells, of about 15 million cells, of about 10 million cells, of about 5 million cells, of about 4 million cells, of about 3 million cells, of about 2 million cells, of about 1 million cells, of about 0.5 million cells, of about 0.25 million cells or of less than 0.25 million cells of a defined mesenchymal stem cell population.

Abstract: Provided herein are compositions and methods for the inhibition of enteric infection. In particular, compositions comprising bacteria of the class Clostridia are administered to human and/or animal subjects to prevent or decrease susceptibility to enteric infection.

Abstract: A composition for increasing dermal nitric oxide comprises in combination, a quantity of beet root extract, a quantity of aloe vera extract, a quantity of willow bark extract and a quantity of curcumin powder suspended in a base suitable for application to the skin of a user. The composition may be formed by providing the base suitable for application to the skin of a user and suspending within the base, in combination, a quantity of beet root extract, a quantity of aloe vera extract, a quantity of willow bark extract and a quantity of curcumin powder.

Abstract: The present application provides use of an algal proteoglycan extract and a composition comprising the same in treating or preventing tumor, pain, inflammation or diseases mediated by inflammatory factors.

Abstract: Producing a resin from an organic waste product includes assessing a weight percent of a first volatile fatty acid and a weight percent of a second volatile fatty acid in a liquid mixture having volatile fatty acids from the organic waste product. The weight percent of the volatile fatty acids is based on the total weight of the carboxylic acids in the liquid mixture, the total weight of volatile fatty acids in the liquid mixture, or the total weight of lactic acid and volatile fatty acids in the mixture. A ratio of the weight percent of the first volatile fatty acid to the weight percent of the second volatile fatty acid in the liquid mixture is adjusted to yield a modified liquid mixture. The modified liquid is combined with polyhydroxyalkanoate-producing bacteria to yield a polyhydroxyalkanoate copolymer; and the polyhydroxyalkanoate copolymer is extracted from the polyhydroxyalkanoate-producing bacteria.

Abstract: Compositions containing probiotics and a nitric oxide precursor such as L-arginine to enhance nitric oxide production in animals and methods for improving immunity, gut barrier functions, and gut health and treating gastroenteritis and mucositis in animals using same.

Abstract: Provided herein are agents, compositions, and methods for agricultural use, e.g., for altering the level, activity, or metabolism of one or more microorganisms resident in a host nematode or arthropod (e.g., honeybee or silkworm), the alteration resulting in an increase in the fitness of the host. The invention features a composition that includes an agent (e.g., phage, peptide, small molecule, antibiotic, or combinations thereof) that can alter the host's microbiota in a manner that is beneficial to the host. By promoting favorable microbial levels, microbial activity, microbial metabolism, and/or microbial diversity, the agents described herein may be used to increase the fitness of a variety of beneficial nematodes or arthropods, such as bees and silkworms, utilized in agriculture and commerce.

Abstract: The present invention relates to recombinant cyanobacterial cells for the production of a chemical compound of interest. In particular, the present invention relates to genetic modifications that introduce one or more heterologous phosphopantetheinyl transferases (PPTases) into a cyanobacterial cell. These cells can, optionally, further comprise heterologous carrier protein and nucleic acid constructs that provide the cyanobacterial cells with the capability of producing chemicals of interest or compounds of interest, such secondary metabolites polyketides, nonribosomal peptides and their hybrids, the three major families of bioactive natural products, of cyanobacteria and other bacterial phyla, secondary metabolites analogs, and unnatural compounds.

Abstract: The apparatuses described herein relate to preparation of a meat product. Apparatuses, systems comprising the apparatuses, and methods of making and use the systems and apparatuses are described herein. These are useful for controlling one or more of growth on and separation of a meat product from an enclosed substrate. The apparatuses and systems are configured to receive fluid and grow the meat product and/or separate the meat product from the substrate in a scalable manner.

Abstract: The present invention provides compositions and methods for improving the quality of life for a subject, particularly a child, diagnosed with autism spectrum disorder (ASD). In preferred embodiments, a supplement composition comprising natural or naturally-derived ingredients is delivered to a subject in the form of a chocolate bar or other candy alongside administration of an antiviral medication. Advantageously, the composition and methods can improve the immune health of the subject, along with other signs and symptoms associated with ASD, infections and other immunocompromising conditions.

Abstract: The present invention relates to a method for producing marine algae-derived agarotriose, and a use thereof as a prebiotic. More specifically, the present invention investigates the characteristics of agarotriose as a prebiotic which is selectively metabolized by probiotic microorganisms, thereby enabling agarotriose to be used as an anti-cancer or anti-inflammatory agent in the fields of food and pharmaceuticals, and enabling agarotriose to be obtained at high yield through efficient purification with minimal loss after enzymatic hydrolysis of a red algae-derived polysaccharide without pre-treatment.

Abstract: The subject invention pertains to methods and compositions for the treatment of erectile dysfunction (ED) (e.g., impotence) in a subject in need thereof utilizing one or more cannabinoid and one or more anti-ED drug.

Abstract: The present invention provides a bacterium and a method for the biological production of Heliotropin by the fermemtation of safrole. In one aspect of the present invention, a process for the conversion of safrole to Heliotropin is achieved by the use of a bacterial strain of Serratia liquefaciens ZMT-1 (CCTCC M 2016170). The production method comprises the steps of seeding the Serratia liquefaciens culture in the presence of oxygen for 24-36 hours, transforming the safrole substrate for 24-48 hours with 0.5-3 g/L substrate concentration, and reaching the Heliotropin concentration of 160-524 mg/L. The present invention reports, for the first time, on a method for producing the high concentration of Heliotropin by using the Serratia liquefaciens ZMT-1 strain or the enzyme extracted from the strain.

Abstract: The invention is directed to a culture medium for Haematococcus that contains combustion gases like carbon dioxide, carbon monoxide, and oxides of nitrogen or sulfur and which fixes the carbon, nitrogen or sulfur in these combustion gases into biomass and to methods providing superior biomass yields using this culture medium to culture select species of Haematococcus such as Haematococcus sp. KAU-01.